Mounjaro vs Foundayo: Full Comparison (2026)
How does Mounjaro (Tirzepatide) compare to Foundayo (Orforglipron)? We break down the weight loss data, pricing, side effects, and who each medication is best suited for.
Mounjaro (Tirzepatide, Dual GLP-1/GIP receptor agonist) and Foundayo (Orforglipron, Oral non-peptide GLP-1 receptor agonist) work through different mechanisms. Mounjaro is FDA-approved for type 2 diabetes with 15-22% of body weight average weight loss at $1,023/mo. Foundayo is approved for chronic weight management with up to 12.4% of body weight (ATTAIN-1, top dose) average weight loss at $149/mo.
Side-by-Side Comparison
| Feature | Mounjaro | Foundayo |
|---|---|---|
| Active Ingredient | Tirzepatide | Orforglipron |
| Mechanism | Dual GLP-1/GIP receptor agonist | Oral non-peptide GLP-1 receptor agonist |
| FDA Approved For | Type 2 diabetes | Chronic weight management |
| Doses | 2.5mg to 15mg (weekly injection) | 0.8mg start, titrating every 4 weeks to 5.5mg, 9mg, or 17.2mg (once-daily pill) |
| Administration | Weekly subcutaneous injection | Once-daily oral tablet — no food or water restrictions |
| Avg. Weight Loss | 15-22% of body weight | up to 12.4% of body weight (ATTAIN-1, top dose) |
| Monthly Price | $1,023 | $149 |
| Oral Available | No | Yes |
| Year Approved | 2022 | 2026 |
Prices reflect typical self-pay costs without insurance. Actual costs vary by pharmacy, location, and insurance plan. Last updated March 2026.
Which Produces More Weight Loss?
Based on clinical data, Mounjaro produces more weight loss on average (15-22% of body weight) compared to Foundayo (up to 12.4% of body weight (ATTAIN-1, top dose)). Mounjaro uses Tirzepatide (Dual GLP-1/GIP receptor agonist), while Foundayo uses Orforglipron (Oral non-peptide GLP-1 receptor agonist), which may account for the difference.
First dual GLP-1/GIP receptor agonist. Approved for type 2 diabetes, used off-label for weight loss. Generally shows greater weight loss than semaglutide alone.
The first oral small-molecule GLP-1 approved for weight loss (FDA approved April 1, 2026). A once-daily pill taken with no food or water restrictions. Lower peak efficacy than injectable tirzepatide or semaglutide, but far cheaper cash-pay at $149/month and far more convenient — no needles.
Which Costs Less?
At list price, Foundayo is the more affordable option at $149/month compared to $1,023/month for Mounjaro. However, actual out-of-pocket costs depend heavily on your insurance plan. Mounjaro with insurance: $25-$200/month with Lilly savings card. Foundayo with insurance: $50/mo via Medicare Bridge; ~$25/mo with eligible commercial coverage.
Eli Lilly savings card for eligible patients
$149/month cash via LillyDirect (no insurance required)
Side Effects Comparison
Both Mounjaro (Dual GLP-1/GIP receptor agonist) and Foundayo (Oral non-peptide GLP-1 receptor agonist) share similar gastrointestinal side effects, which are the most commonly reported:
- Nausea (most common for both medications)
- Diarrhea and vomiting
- Constipation
- Abdominal pain
- Decreased appetite
- Headache, fatigue, dizziness (less common)
Serious but rare side effects for both include pancreatitis, gallbladder problems, and kidney issues. Both carry warnings about medullary thyroid carcinoma risk based on animal studies. Always discuss your full medical history with your doctor before starting either medication.
Which Should You Choose?
The best choice depends on your diagnosis, insurance coverage, weight loss goals, and personal preferences. Here is our general guidance:
- -You have type 2 diabetes (on-label use, better insurance coverage)
- -Cost is a concern ($1,023/month at list price)
- -You want the dual GLP-1/GIP mechanism for potentially greater efficacy
- -You prefer the convenience of once-weekly dosing
- -Your primary goal is weight loss (FDA-approved indication)
- -You prefer an oral option over injections
- -Cost is a concern ($149/month at list price)
- -You prefer a daily dosing routine
Find the Best GLP-1 Provider for You
Compare verified telehealth programs that prescribe Mounjaro, Foundayo, and other FDA-approved GLP-1 medications.
Frequently Asked Questions
Can I switch from Mounjaro to Foundayo?
Switching between Mounjaro and Foundayo is possible but requires medical supervision since they contain different active ingredients (Tirzepatide vs Orforglipron). Your doctor will determine the appropriate starting dose and titration schedule for the new medication.
Which is better for weight loss: Mounjaro or Foundayo?
Clinical data suggests Mounjaro produces more weight loss on average (15-22% of body weight) compared to Foundayo (up to 12.4% of body weight (ATTAIN-1, top dose)). However, individual results vary significantly based on dosing, diet, exercise, and metabolic factors.
Is Mounjaro cheaper than Foundayo?
At list price, Foundayo ($149/month) is less expensive than Mounjaro ($1,023/month). With insurance, costs vary significantly. Mounjaro: $25-$200/month with Lilly savings card. Foundayo: $50/mo via Medicare Bridge; ~$25/mo with eligible commercial coverage.
Do Mounjaro and Foundayo have the same side effects?
Both medications share similar gastrointestinal side effects (nausea, diarrhea, vomiting, constipation) as these are common to GLP-1 receptor agonists. However, since they contain different active ingredients, there may be differences in frequency and severity. Discuss your medical history with your doctor to determine which has a better safety profile for you.
Does insurance cover Mounjaro and Foundayo?
Coverage varies by plan. Mounjaro is FDA-approved for type 2 diabetes — insurance coverage is typically better for on-label use. Foundayo is FDA-approved for chronic weight management. Check with your specific insurance plan and ask your doctor about prior authorization requirements.